Invasive Candida Infections Outbreak

Candida species are commensals of the human gastrointestinal microbiota and skin; but may translocate to the bloodstream and causing life threatening infections. Invasive Candida infections (ICI) is an increasing threat to patients in the ICU; patients undergoing complicating or repeating gastrointestinal surgery; and for immuno compromised patients, e.g., cancer patients, or recipients of solid organ or stem cell transplants.

As invasive candida infections are among the most common bloodstream infections; and are associating with high morbidity and mortality. CandiReg servings as platform for international cooperation; and studies on attributable mortality; but candida reactive T cells; evaluations of guideline adherence, and recently the third multicenter ECMM study on incremental costs associating with nosocomial invasive candidiasis in Europe; CANDIDA III was initiating taking advantage of this platform.

Candida infections outbreak

But coming to details on management including antifungal treatment ; recording drug, dose, duration, route of administration, therapeutic drug monitoring, reason for stopping; drug relating adverse events and surgical procedures, catheter management; clearance of bloodstream infection or infectingf sites are documenting.

But treatment indication is differentiated into prophylaxis; empiric, pre-emptive and targeting treatment for ambulatory; and inpatient parenteral antifungal therapy. Response to antifungal therapy is evaluating after two and four weeks, three and six months and on the final day of observation. In addition, treatment response and outcome of the underlying disease as well as potential prolongation of hospital stay are also documented.

Attributable mortality

But however, information on outcome includes overall mortality and attributable mortality. If available, autopsy results are recording. Quality Management is covering once yearly from participating centers; with regard to guideline implementation and adherence.

But candiReg provides an eCRF for invasive Candida infections that can be used for a variety of studies from cohort studies on attributable mortality to evaluations of guideline adherence, offering to the investigators of the 28 ECMM member countries the opportunity to document their cases of invasive Candida infection. But this candiReg allowing the monitoring of epidemiology of invasive Candida infections; including monitoring of multinational outbreaks. Here, we describe the structure and management of the CandiReg platform.